Ocular Hypertension

Skye Bioscience has completed enrollment for its phase 2a trial of SBI-100, a cannabinoid receptor type 1 agonist being developed for patients with primary open-angle glaucoma or ocular hypertension, according to a company press release.

Patients receiving ocular steroid injections may be at higher risk for developing glaucoma or ocular hypertension, even without prior diagnosis or treatment, according to research published in BMJ Open Ophthalmology.

Yoga headstand, bellows breath and control of breathing technique transiently worsened IOP in a cohort of practicing yoga volunteers and may cause pressure-related damage to the eye, according to research published in Maedica.

Nicox announced that the first patient has been screened in its Whistler phase 3b clinical trial of NCX 470, a nitric oxide-donating bimatoprost eye drop designed to lower IOP in patients with open-angle glaucoma or ocular hypertension.

The FDA approved the iDose TR for the lowering of IOP in patients with ocular hypertension or open-angle glaucoma, according to a press release from Glaukos.

Skye Bioscience has treated the first patient in its phase 2 study of SBI-100 ophthalmic emulsion, a CB1 agonist delivered as an eye drop to treat patients with elevated IOP, according to a company press release.

Thea Pharma has launched Iyuzeh in the U.S. for the treatment of primary open-angle glaucoma or ocular hypertension.

Patients with ocular hypertension may undergo visual field tests every 6 months if they are at high or medium risk for progression to primary open-angle glaucoma, and every 12 months if they are at low risk, according to a study.

NEW ORLEANS — In this Healio video perspective, Michael Chaglasian, OD, FAAO, discusses the diagnostic efficacy of a modified Ocular Hypertension Treatment Study risk calculator, which he presented in a poster at the ARVO meeting.

Polygenic risk score is associated with an increased risk for primary open-angle glaucoma in patients with ocular hypertension, according to a speaker.